LAMP2 and prostate carcinoma: Other experimental investigations demonstrated that sulforaphane therapy promotes the expression of a lysosome-associated membrane protein 2 (LAMP2), which decreases sulforaphane’s capacity to trigger apoptotic cell death, at least in prostate cancer.